WO2025041077 - CTLA-4-BASED LYSOSOMAL DEGRADERS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/041077
Publication Date
27.02.2025
International Application No.
PCT/IB2024/058185
International Filing Date
22.08.2024
Title **
[English]
CTLA-4-BASED LYSOSOMAL DEGRADERS AND USES THEREOF
[French]
AGENTS DE DÉGRADATION LYSOSOMAUX À BASE DE CTLA-4 ET LEURS UTILISATIONS
Applicants **
SANOFI
Inventors
CONDIFF, Emily
MUKAI, Kaori
PARK, Sunghae
NIEBEL, Björn
SUN, Victor Zhao
ZHOU, Qun
Priority Data
23192970.4
23.08.2023
EP
63/674,517
23.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4390 | |
| EPO | Filing, Examination, Granting | 61428 | |
| Japan | Filing, Examination, Granting | 4069 | |
| South Korea | Filing, Examination, Granting | 5874 | |
| USA | Filing, Examination, Granting | 18790 |
Total:
94,551
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides a method for degrading a target protein, comprising: contacting a T-cell with a multispecific binding protein, wherein the multispecific binding protein comprises: a) a first cell surface binding moiety that specifically binds to membrane- bound CTLA-4 on the surface of the T-cell; and b) a second binding moiety that is operatively linked to the first cell surface binding moiety and that specifically binds to the target protein, wherein binding of the multispecific binding protein to the membrane-bound CTLA-4 on the surface of the T-cell facilitates the internalization of the target protein by the T-cell. After internalization, the multispecific binding protein plus the target protein traffic to a lysosome within the T-cell, enabling degradation of the target protein within the lysosome. The present disclosure also provides multispecific binding protein compositions, host cells for making the multispecific binding protein compositions, and methods of using the multispecific binding protein compositions to treat disease.[French]
La présente divulgation concerne un procédé de dégradation d'une protéine cible, comprenant : la mise en contact d'un lymphocyte T avec une protéine de liaison multispécifique, la protéine de liaison multispécifique comprenant : a) une première fraction de liaison de surface cellulaire qui se lie de manière spécifique à CTLA-4 liée à la membrane sur la surface du lymphocyte T ; et b) une seconde fraction de liaison qui est liée de manière fonctionnelle à la première fraction de liaison de surface cellulaire et qui se lie de manière spécifique à la protéine cible, la liaison de la protéine de liaison multispécifique à CTLA-4 liée à la membrane sur la surface de lymphocyte T facilitant l'internalisation de la protéine cible par le lymphocyte T. Après internalisation, la protéine de liaison multispécifique plus le trafic de protéine cible vers un lysosome à l'intérieur du lymphocyte T, permettant la dégradation de la protéine cible à l'intérieur du lysosome. La présente invention concerne également des compositions de protéines de liaison multispécifiques, des cellules hôtes pour fabriquer les compositions de protéines de liaison multispécifiques, et des procédés d'utilisation des compositions de protéines de liaison multispécifiques pour traiter une maladie.